| Trial ID: | L3715 |
| Source ID: | NCT02290301
|
| Associated Drug: |
Gemigliptin
|
| Title: |
An Observational Study to Evaluate Cardiovascular Outcomes of T2DM PatientsTreated With Gemigliptin
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: gemigliptin
|
| Outcome Measures: |
Primary: Time-to-event for the primary composite MACE(Major Adverse Cardiovascular Events) endpoint, during the study period (2~4 years) |
|
| Sponsor/Collaborators: |
Sponsor: LG Life Sciences
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
5180
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2013-06-28
|
| Completion Date: |
2017-11-30
|
| Results First Posted: |
|
| Last Update Posted: |
2019-01-24
|
| Locations: |
Pusan National University Hospital, Busan, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT02290301
|
